FDA Issues Guidance on Cancer Trial Washout Periods, Medications
July 28, 2026
July 28, 2026
WASHINGTON, July 28 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has issued final guidance recommending how sponsors, institutional review boards and clinical investigators should use washout periods and concomitant medication exclusions in cancer clinical trials.
The guidance, "Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications," applies to trials of investigational drugs regulated by the Cen . . .
The guidance, "Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications," applies to trials of investigational drugs regulated by the Cen . . .